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The burden of Duchenne muscular
dystrophy
An international, cross-sectional study
ABSTRACT
Objective: The objective of this study was to estimate the total cost of illness and economic
burden of Duchenne muscular dystrophy (DMD).
Methods: Patients with DMD from Germany, Italy, United Kingdom, and United States were iden-
tified through Translational Research in Europe–Assessment & Treatment of Neuromuscular
Diseases registries and invited to complete a questionnaire online together with a caregiver. Data
on health care use, quality of life, work status, informal care, and household expenses were col-
lected to estimate costs of DMD from the perspective of society and caregiver households.
Results: A total of 770 patients (173 German, 122 Italian, 191 from the United Kingdom, and
284 from the United States) completed the questionnaire. Mean per-patient annual direct cost
of illness was estimated at between $23,920 and $54,270 (2012 international dollars), 7 to
16 times higher than the mean per-capita health expenditure in these countries. Indirect and
informal care costs were substantial, each constituting between 18% and 43% of total costs.
The total societal burden was estimated at between $80,120 and $120,910 per patient and an-
num, and increasedmarkedly with disease progression. The corresponding household burden was
estimated at between $58,440 and $71,900.
Conclusions: We show that DMD is associated with a substantial economic burden. Our results
underscore the many different costs accompanying a rare condition such as DMD and the consid-
erable economic burden carried by affected families. Our description of the previously unknown
economic context of a rare disease serves as important intelligence input to health policy evalua-
tions of intervention programs and novel therapies, financial support schemes for patients and
their families, and the design of future cost studies. Neurology® 2014;83:529–536
GLOSSARY
CI5 confidence interval;DMD5Duchenne muscular dystrophy; RR5 relative risk; TREAT-NMD5 Translational Research in
Europe–Assessment & Treatment of Neuromuscular Diseases.
Rare diseases, although by definition individually uncommon, are associated with a tremendous
health burden globally. In the European Union, an estimated 30 million people are affected by
diseases with a prevalence of less than 1 in 2,000,1 and a similar number has been reported for
diseases affecting fewer than 200,000 individuals (about 1 in 1,250) in the United States.2 Many
rare diseases are chronic and life-threatening, accompanied by substantial morbidity, extensive
health care needs, and considerable psychological and financial stress for affected families.3 Still,
little is known of their economic burden beyond direct medical costs.
The lack of comprehensive cost data for rare conditions is well illustrated in the case of
Duchenne muscular dystrophy (DMD), an X-linked neuromuscular disease with a birth inci-
dence of about 1 in 3,800–6,300.4 Patients with DMD have muscle weakness from early
childhood requiring wheelchair use from usually the early teens with fatal complications due
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to cardiac and respiratory involvement in early
to mid adult life. The natural history of the
disease is relatively well understood, care
guidelines are available to assist optimum
care,5,6 and several therapeutic modalities are
currently in trial. Nonetheless, little is known
of the costs associated with DMD.
The objective of this study was to estimate
the total economic burden of DMD to society
and caregiver households. Our aim was to
identify costs of particular importance to rare
diseases in general to help policymakers devise
appropriate intervention programs, inform
financial support schemes for patients and
their families, and facilitate evaluations of
new treatments.
METHODS Participants and procedures.We identified pa-
tients with DMD from Germany, Italy, United Kingdom, and
United States through national DMD registries, which form part
of the global Translational Research in Europe–Assessment &
Treatment of Neuromuscular Diseases (TREAT-NMD) network.7
All 4 registries have been in operation for at least 7 years, ensuring
good representation across age groups. To be eligible, patients were
required to fulfill the following criteria: (1) male, (2) DMD diag-
nosis, and (3) age 5 years or older. Patients who were from
Germany, Italy, United Kingdom, or United States but currently
resided in a different country were not eligible for participation.
Eligible patients and one of their caregivers (e.g., parent) were
invited to complete a questionnaire online. The questionnaire
consisted of questions regarding the patient (demographic infor-
mation, health status, and DMD-related health care resource use)
as well as the caregivers, their households, and DMD-related ex-
penses. Recall periods were specified depending on the frequency
of resource use in clinical practice and care guidelines5,6 (1 month,
6 months, or 1 year). Patient and caregiver quality-of-life data
were collected using the Health Utilities Index8 and EuroQol
EQ-5D9 instrument, respectively. Study materials were presented
in the native language of each country and subject to review by
the TREAT-NMD coordination team to ensure understandabil-
ity, accuracy, and completeness. A pilot study was conducted to
further establish questionnaire validity. Recruitment started July
2012 and ended July 2013.
Standard protocol approvals, registrations, and patient
consents. All participants provided informed consent. Study ethical
approval was granted from Ludwig-Maximilians-Universität Mün-
chen (Germany), Comitato Etico IRCCS E. Medea–Associazione
La Nostra Famiglia (Italy), North East Research Ethics Service,
NHS (United Kingdom), and the Western Institutional Review
Board (United States). Approval was also obtained from the
TREAT-NMD Global Databases Oversight Committee.
Statistical analysis. Cost of care was calculated from a societal
perspective and annualized by multiplication under the assump-
tion that a similar proportion of subjects would use the same
quantity of resources in any given 1-month, 6-month, or 1-year
period. We applied local reference prices10–18 to the health care
resource data to produce estimates of direct cost of illness.
Country-specific costs for aids, devices, and investments were
obtained through expert input from TREAT-NMD partners.
Indirect cost (societal loss of production) of DMDwas valued
according to the Human Capital approach at the cost of employ-
ment. Outcomes from the Work Productivity and Activity
Impairment Questionnaire19 were used to estimate productivity
losses due to absenteeism and impaired productivity while
working.
Intangible cost (costs due to pain, anxiety, social handicap,
etc.) was estimated by assigning a monetary value to the loss in
quality of life for patients and caregivers in relation to the age-
and sex-specific mean quality of life in the general population.
The societal willingness-to-pay for 1 year of full health, also
known as 1 quality-adjusted life-year, varies by method of assess-
ment and setting, and frequently cited values lie between $50,000
and $100,000.20 In this study, a willingness-to-pay for a quality-
adjusted life-year of $75,000 was used in the analysis.
We valued each hour of paid informal care according to the
Human Capital approach. To estimate unpaid informal care, we
first calculated the proportion of the caregivers’ leisure time devoted
to informal care, estimated using outcomes from theWork Produc-
tivity and Activity Impairment Questionnaire and data from the
Organisation for Economic Co-operation and Development on the
country-specific mean daily number of hours of leisure time for an
adult in the general population.21 Each hour of leisure time was then
conservatively valued at 35% of the country-specific national mean
gross wage, in line with previous research and recently updated
estimates of the value of travel time savings.22,23
The economic burden on the household for caring for a boy
with DMD was calculated for caregiver households in which the
patients with DMD currently lived. We estimated the loss of
household income as a result of reducing working hours or stop-
ping work completely because of their son’s DMD by calculating
the difference between the country-specific national median
equalized household disposable income and the self-reported
equalized household disposable income.
We related our results to the progression of DMD by classi-
fying patients into 4 groups defined in terms of current ambula-
tory status and age: (1) early ambulatory (age 5–7 years), (2) late
ambulatory (age 8–11 years), (3) early nonambulatory (age 12–15
years), and (4) late nonambulatory (age 16 years or older).
A generalized linear model was fitted to the data to investigate
whether the mean per-patient annual cost of illness varied among
the 4 ambulatory classes (included as proxies for disease progres-
sion) and to predict costs for these groups. To control for con-
founding effects, the generalized linear model was adjusted for
country, household income class, diagnosis of common mental
and behavioral disorders, as well as a dummy variable indicating
additional household member with DMD. Determinants of
patient quality of life and annual household economic burden
were investigated analogously.
Results are presented in 2012 international (United States)
dollars calculated using purchasing power parity data from Eurostat.
The significance level was set to 5%. All analyses were conducted
in Stata 11 (StataCorp LP, College Station, TX). We provide
descriptions of the proprietary instruments used in the study in
appendix e-1 on the Neurology® Web site at Neurology.org.
Additional analysis details provided upon request.
RESULTS A total of 2,346 patients were invited to
participate in the study. Of those, 18 were not eligible
(lived in a different country), 996 provided informed
consent and started to complete the questionnaire,
and 770 patient-caregiver pairs completed all
sections of the questionnaire (table 1). The overall
study response rate was 42%. In the pooled sample,
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patients had a mean age of 14 years (range 5–43) and
a median age of 12 years (interquartile range 9–17).
The majority of caregivers were mothers to the
participating patients with DMD.
Cost of illness. Participating patients indicated the use
of many different types of health care resources,
including a wide variety of medical devices and aids,
medications, tests and assessments, and admissions
to hospitals. Patients also made a large number of vis-
its to physicians and other health care practitioners,
predominantly physiotherapists. Informal care (care-
givers’ nonprofessional paid care and the proportion
of caregivers’ leisure time devoted to provide informal
care) was extensive in all countries. Labor-force
participation among patients was very low (,4%)
and many caregivers had reduced their working
hours, or stopped working completely, because of
their son’s DMD. For employed caregivers, the
mean overall work impairment (loss in work time
and productivity while working) was estimated at
20% (95% confidence interval [CI]: 16%–25%) for
the German sample, and 24% (18%–31%), 29%
(24%–35%), and 27% (23%–31%) for the Italian,
UK, and US sample, respectively.
Costs associated with DMD-related health care
resource use, informal care, and production losses (indi-
rect costs) are presented in table 2. The largest cost
component was indirect costs in Germany, Italy, and
the United States, and nonmedical community services
in the United Kingdom (figure 1). Figure 2 presents cost
estimates stratified by ambulatory class. The mean per-
patient annual direct medical cost of DMD was esti-
mated at $11,240 (95% CI: $9,720–$14,100), $7,300
($5,770–$9,670), $15,940 ($13,580–$20,610), and
$28,590 ($25,030–$35,870), for German, Italian,
UK, and US patients, respectively.
Quality of life (intangible costs). Mean proxy-assessed
Health Utilities Index–derived utility (0 indicating
death, 1 perfect health) was estimated at 0.45 (95%
CI: 0.41–0.51), 0.52 (0.45–0.58), 0.43 (0.39–0.47),
and 0.45 (0.42–0.49) for patients from Germany,
Italy, United Kingdom, and United States,
respectively. Corresponding EQ-5D utility estimates
for the caregivers were 0.79 (95% CI: 0.76–0.82),
0.84 (0.81–0.86), 0.82 (0.79–0.84), and 0.81
(0.78–0.83). The mean loss of quality of life in
relation to the general population was estimated at
0.48 (0.46–0.51) and 0.11 (0.10–0.12) for patients
Table 1 Demographic characteristics of the study participants (n 5 770 patient-caregiver pairs)
Germany Italy United Kingdom United States
Patients
No. (%) 173 (100) 122 (100) 191 (100) 284 (100)
Age, y 13 (9–17) 12 (8–17) 12 (8–17) 12 (9–17)
Ambulatory class, n (%)
Early ambulatory (age 5–7 y)a 30 (17) 31 (25) 46 (24) 48 (17)
Late ambulatory (age 8–11 y)a 49 (28) 35 (29) 62 (32) 110 (39)
Early nonambulatory (age 12–15 y)b 47 (27) 24 (20) 34 (18) 49 (17)
Late nonambulatory (age 16 y or older)b 47 (27) 32 (26) 49 (26) 77 (27)
Ventilation support, n (%) 26 (15) 24 (20) 35 (18) 41 (14)
Caregivers
No. (%) 173 (100) 122 (100) 191 (100) 284 (100)
Sex, male, n (%) 28 (16) 42 (34) 41 (21) 50 (18)
Age, y 45 (40–49) 45 (41–50) 44 (39–50) 43 (39–50)
Relationship to the patient, n (%)
Parent to the patient 169 (98) 121 (99) 188 (98) 275 (97)
Other relative of the patient 3 (2) 1 (1) 3 (2) 7 (2)
Friend or partner of the patient 1 (,1) 0 (0) 0 (0) 2 (,1)
Employed, n (%) 102 (59) 73 (60) 105 (55) 189 (67)
Reduced working hours or stopped working
completely because of relative’s DMD, n (%)
74 (43) 35 (29) 93 (49) 77 (27)
Abbreviation: DMD 5 Duchenne muscular dystrophy.
Data presented as n (%) or median (interquartile range). Because of rounding, percentages might not add up to exactly
100%.
aAn ambulant patient older than the specified age intervals was included in the late ambulatory patient group.
bA nonambulant patient younger than the specified age intervals was included in the early nonambulatory patient group.
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and caregivers, respectively. Associated intangible
costs are presented in table 2. Figure 2 presents
mean patient utility stratified by ambulatory class.
Total economic burden of illness. Estimates of the total
economic burden of DMD, including a monetary
value of the loss in patient and caregiver quality of life
(intangible costs), are presented in table 2. Using the
most recent DMD prevalence estimates,7 the national
burden of DMD in Germany, Italy, United Kingdom,
and United States was estimated at $278,058,000,
$154,465,000, $200,478,000, and $1,217,373,000,
respectively.
Household economic burden of DMD. The mean per-
patient annual household economic burden of
DMD, calculated for households in which the
patients with DMD currently lived, is presented in
table 3. Total out-of-pocket payments were notably
higher in the US sample. The mean activity
impairment (ability to perform regular daily
activities) due to the son’s DMD was estimated at
39% (95% CI: 35%–44%), 34% (29%–40%),
42% (38%–46%), and 34% (31%–37%) for
German, Italian, UK, and US patients, respectively.
This corresponds to a weekly loss of approximately
41, 36, 44, and 33 hours of leisure time. Adjusted
regression analysis results showed that patients in the
late ambulatory, early nonambulatory, and late
nonambulatory classes had 38% (relative risk [RR]:
1.38, 95% CI: 1.20–1.59), 181% (RR: 2.81, 95%
CI: 2.41–3.27), and 191% (RR: 2.91, 95% CI:
2.54–3.34) higher annual household economic
burden compared with their early ambulatory
counterparts.
DISCUSSION The aim of this study was to estimate
the total cost and economic burden of DMD from
the perspective of society and caregiver households.
We estimated the mean per-patient annual direct
cost of DMD at $42,360, $23,920, $54,160, and
$54,270 for patients from Germany, Italy, United
Kingdom, and United States, approximately 10, 8,
Table 2 Per-patient annual costs of DMD (in 2012 international dollars)
Germany Italy United Kingdom United States
Hospital admissionsa 2,080 (1,020–4,950) 1,420 (900–2,470) 2,300 (1,500–3,720) 2,220 (900–5,050)
Visits to physicians and
other health care
practitioners
3,850 (3,410–4,340) 2,590 (1,970–3,440) 8,230 (6,360–13,150) 18,210 (15,450–22,260)
Nurse 40 (10–80) 40 (10–220) 550 (300–1,160) 1,270 (650–2,530)
General practitioner 110 (80–160) 40 (30–60) 340 (220–670) 230 (180–340)
Specialist physician 330 (280–410) 170 (130–240) 3,290 (2,380–7,100) 3,730 (3,140–4,840)
Psychologist or therapist 50 (30–110) 50 (30–120) 160 (80–390) 720 (430–1,220)
Physiotherapist or
occupational therapist
2,810 (2,480–3,180) 2,210 (1,610–3,020) 3,290 (2,420–5,820) 9,920 (8,220–12,030)
Other health care
practitionerb
500 (360–700) 70 (50–120) 600 (370–1,400) 2,350 (1,740–3,200)
Tests and assessments 2,400 (2,180–2,680) 600 (530–690) 1,580 (1,450–1,750) 2,860 (2,660–3,070)
Medications 1,020 (770–2,000) 1,550 (890–4,650) 930 (820–1,070) 2,070 (1,720–2,710)
Nonmedical community
servicesc
8,920 (6,890–12,400) 2,740 (1,640–5,380) 19,250 (13,240–28,670) 7,610 (6,030–9,790)
Aids, devices, and
investmentsd
5,560 (4,160–7,460) 1,850 (970–4,450) 7,520 (5,690–9,790) 7,930 (6,210–10,260)
Informal care 18,530 (16,440–20,580) 13,160 (11,270–15,280) 14,340 (13,030–15,990) 13,370 (12,060–14,930)
Total direct cost of illness 42,360 (38,640–46,880) 23,920 (20,420–28,300) 54,160 (47,310–63,510) 54,270 (48,740–62,220)
Indirect cost of illness
(production losses)
20,770 (17,670–24,250) 18,220 (15,430–21,380) 18,700 (16,280–21,150) 21,550 (18,490–24,720)
Total annual cost of illness 63,140 (57,600–69,710) 42,140 (36,940–47,730) 72,870 (64,350–84,150) 75,820 (69,350–85,270)
Intangible costs 45,860 (41,630–50,160) 37,980 (32,400–43,550) 46,080 (42,360–50,050) 45,080 (41,100–48,260)
Total burden of illness 109,000 (100,390–119,510) 80,120 (71,030–89,190) 118,950 (108,280–132,710) 120,910 (111,460–130,770)
Abbreviation: DMD 5 Duchenne muscular dystrophy.
Data presented as mean (95% confidence interval), rounded to nearest 10.
a Including emergency and respite care.
bCare coordinator/care advisor, dentist, dietitian/nutritionist, and speech/language/swallowing therapist.
c Home help, personal assistants, nannies, and transportation services.
d Include investments to and reconstructions of the home (e.g., adaptations for wheelchair accessibility).
532 Neurology 83 August 5, 2014
16, and 7 times higher than the mean per-capita
health expenditure in these countries,24 respectively.
These results suggest that the medical management of
the disease in the United Kingdom is considerably
more resource intensive relative to that of the
general population compared with the other
countries, a finding possibly explained by national
differences in the general provision of health care or
DMD care in particular. We also found differences
among countries regarding costs of specific resource
types, in particular visits to physicians and other
health care practitioners, nonmedical community
services, and informal care. Nonetheless, with the
exception of Italy (because of relatively lower
resource use and tariff prices), direct cost of illness
was in absolute numbers remarkably similar across
countries.
Comparing our results with previous research into
conditions similar to DMD, our estimate of the direct
medical cost for the US sample ($28,590) was strik-
ingly similar to the annual medical care expenditures
for a mixed population of patients with muscular dys-
trophy in a privately insured US cohort reported by
Ouyang et al.25 ($24,880), as well as the annual med-
ical cost for a mixed group of patients with muscular
dystrophy recently reported by Larkindale et al.26
($24,122). However, our study is unique in targeting
a single rare disease and taking an international per-
spective, as well as showing that additional key cost
elements not considered in these other studies
Figure 1 Components of annual cost of Duchenne muscular dystrophy
Hospital admissions include emergency and respite care. Nonmedical community services refer to home help, personal as-
sistants, nannies, and transportation services. Aids, devices, and investments include investments to and reconstructions of
the home (e.g., adaptations for wheelchair accessibility). Because of rounding, percentages might not add up to exactly
100%.
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constitute a significant component of the overall bur-
den of disease.
In addition to direct costs, DMD was also associ-
ated with large production losses, for both patients
and caregivers. Only a trivial proportion of patients
was employed, and between 27% and 49% of care-
givers had reduced their working hours or stopped
working completely because of their son’s DMD.
Potential reasons for these intercountry variations
include differences in the proportion of caregivers
employed, extent of employment (e.g., part-time),
but also the divisions of labor within households,
where in some countries it may be less common for
women to work outside of the home. In addition,
Figure 2 Mean per-patient annual cost of illness and mean proxy-assessed patient utility
Mean per-patient annual cost of illness (columns) and mean proxy-assessed patient utility (connected markers), by country and ambulatory class. Utilities
were obtained through the Health Utilities Index (HUI) instrument. Predicted cost of illness values (lettered columns) were obtained by fitting a generalized
linear model and are interpreted as the mean costs associated with each ambulatory class when adjusting for country, income class, and common mental
and behavioral disorders. Column A: reference. Column B: relative risk (RR) 1.17 (95% confidence interval [CI]: 1.02–1.35). Column C: RR 1.74 (95%
CI: 1.49–2.02). Column D: RR 2.43 (95% CI: 2.12–2.79). Model outcomes for predicted HUI‐derived utility values were as follows. Early ambulatory:
reference. Late ambulatory: RR 0.88 (95% CI: 0.83–0.92). Early nonambulatory: RR 0.30 (95% CI: 0.27–0.34). Late nonambulatory: RR 0.20 (95% CI:
0.17–0.22).
Table 3 Per-patient annual household burden of DMD (in 2012 international dollars)
Germany Italy United Kingdom United States
No. (%) living with caregiver 165 (95) 121 (99) 188 (98) 280 (99)
Total out-of-pocket payments 5,940 (4,240–8,990) 7,550 (3,600–16,470) 3,490 (2,220–5,570) 14,390 (10,300–22,970)
Insurance premiums 150 (60–290) 10 (0–30) 10 (0–30) 6,210 (2,820–14,580)
Copayments for medical services 90 (60–140) 1,160 (130–450) 60 (30–140) 930 (750–1,140)
Copayments for medications 490 (240–1,450) 1,490 (350–4,440) 100 (60–140) 1,470 (1,120–2,070)
Copayments for community services 380 (190–870) 650 (300–2,480) 140 (60–290) 710 (360–1,630)
Out-of-pocket payments for investmentsa 4,830 (3,150–7,670) 4,250 (480–2,350) 3,180 (2,020–5,710) 5,060 (3,130–8,540)
Income loss 1,190 (730–1,880) 620 (310–1,130) 750 (440–1,200) 840 (500–1,360)
Loss of leisure time 17,910 (16,210–20,110) 12,440 (10,710–14,980) 13,590 (12,410–14,980) 11,700 (10,520–12,630)
Intangible costs 45,160 (40,650–49,850) 37,830 (30,220–41,760) 45,770 (42,070–49,670) 45,080 (41,100–48,260)
Total per-patient annual household burden 70,190 (63,760–76,830) 58,440 (50,200–68,900) 63,600 (58,790–68,370) 71,900 (65,520–81,520)
Abbreviation: DMD 5 Duchenne muscular dystrophy.
Data presented as mean (95% confidence interval), rounded to nearest 10, if not otherwise stated.
a Include nonreimbursed payments for medical and nonmedical aids and devices, as well as investments to and reconstructions of the home
(e.g., adaptations for wheelchair accessibility).
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caregivers who did work reported a mean loss in work
time and productivity corresponding to more than
1 day of a 5-day work week. Thus, although our
estimates only include production losses for one care-
giver, indirect costs of DMD are substantial.
Informal caregiving also constituted a major cost
component in all countries (18%–31% of the total
cost of illness). We included informal care as a direct
cost with the rationale that the care otherwise would
have had to be provided by health care professionals.
In fact, in the absence of informal care, our results
suggest that many patients with DMD would require
residence in an institutionalized setting, especially in
the later disease stages.
Patient quality of life was remarkably similar
across countries and significantly lower compared
with general population reference values. The mean
utility in the pooled sample was 0.75, 0.65, 0.24,
and 0.15 for the early ambulatory, late ambulatory,
early nonambulatory, and late nonambulatory class,
respectively, which may be compared with the mean
utility of a healthy 15- to19-year-old boy of 0.94.27
The mean loss of caregiver quality of life in relation to
the general population was 0.11. The detrimental
impact of DMD on quality of life should be con-
sidered in the medical management of the disease to
help provide adequate support to both patients and
caregivers.
Including all costs, we estimated the total societal
burden at between $80,120 and $120,910. It should
be emphasized that these estimates do not include
mortality costs, which are likely to be a major cost
component because of the low life expectancy associ-
ated with DMD. Our results may also not fully cap-
ture costs associated with end-of-life care. For these
reasons, the reported societal burden estimates should
be regarded as conservative.
Households caring for a boy with DMD carry a
large economic burden that increases markedly with
disease progression. We estimated the mean annual
out-of-pocket payments at between $3,490 and
$14,390, and these variations are primarily driven
by differences in the degree of cost-sharing in the
national health care systems, but also the type and
intensity of health care received. Including income
loss, the monetary value of lost leisure time, and
reduced quality of life (intangible costs), the mean
annual household burden of DMD was estimated at
between $58,440 and $71,900. These estimates
should be helpful to inform the support programs
put in place for families caring for a person with
DMD.
It should be noted that we only included the out-
comes of the primary caregiver in our cost and burden
of illness calculations. Informal care and household bur-
den cost estimates were consequently underestimated
for families in which additional individuals, e.g., a sec-
ond parent, sibling, or other close relative, contributed
to the informal DMD care. For this reason, our results
should be regarded as conservative.
A limitation of our study concerns external valid-
ity. Patients were recruited via TREAT-NMD regis-
tries with a mean response rate of 42%.
Participation in the registries is voluntary and
family-initiated; therefore, we cannot rule out a
degree of selection bias. Because the cost of illness
for nonresponders remains unknown, it is also not
possible to assess the extent of the potential bias.
However, given that our sample was fairly evenly dis-
tributed across the defined ambulatory classes, in
addition to the fact that the collected clinical and epi-
demiologic data were characteristic for the different
patient groups (not reported), suggests that the dis-
crepancy between the sample and study population
will be limited.
A second limitation concerns the cross-sectional
study design. Our results are based on a single ques-
tionnaire administration (at one point in time), and
some of the collected resource use data were extrapo-
lated to obtain annual estimates. Thus, there may be
recall bias. Some of our estimates may have been
more sensitive to this type of bias than others, such
as costs related to aids, devices, and investments dur-
ing the last year, where participants may have been
more likely to remember larger expenses. We tried
to alleviate this problem by specifying recall periods
in accordance with standard DMD care, and also
conducted a pilot study with feedback questions to
further improve the validity of the responses.
Our results underscore the wide variety of costs
that accompany a rare disease such as DMD and
the substantial economic burden carried by affected
families. Our results also demonstrate the utility of
global patient registry networks and the need to
develop similar infrastructure to facilitate research of
other diseases. Consideration to the complete eco-
nomic context of rare diseases is essential to fully
understand the benefits of novel therapies and formu-
late sound, affordable, evidence-based health policy.
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